Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Courville, Clifford A ^a   Tidwell, Sherry ^a   Liu, Bo ^a   Accurso, Frank J ^c   Dransfield, Mark T ^a,e,f   Rowe, Steven M ^a,b,d,e,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Children's Hospital Colorado   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CFTR PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BETA ADRENERGIC STIMULATION; BETA ADRENERGIC SWEAT SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DYSPNEA; EVAPORATION; FEMALE; FUNCTION TEST; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOGENESIS; SEX DIFFERENCE; SMOKING; SPIROMETRY; SWEAT CHLORIDE TEST; SWEAT EVAPORIMETRY; SWEATING; COHORT ANALYSIS; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SWEAT;

ADRENERGIC BETA-AGONISTS; ADULT; AGED; COHORT STUDIES; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SWEAT;

EID: 84899486875     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-25     Document Type: Article

References (38)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005, 352:1992-2001. 10.1056/NEJMra043184, 15888700.
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
3. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006, 173:1139-1144. 10.1164/rccm.200508-1330OC, 16497995.
4. Guimbellot JS, Fortenberry JA, Siegal GP, Moore B, Wen H, Venglarik C, Chen YF, Oparil S, Sorscher EJ, Hong JS. Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol 2008, 39:514-521. 10.1165/rcmb.2007-0452OC, 2574524, 18474670.
5. Kreindler JL, Jackson AD, Kemp PA, Bridges RJ, Danahay H. Inhibition of chloride secretion in human bronchial epithelial cells by cigarette smoke extract. Am J Physiol Lung Cell Mol Physiol 2005, 288:L894-L902. 10.1152/ajplung.00376.2004, 15626749.
6. Savitski AN, Mesaros C, Blair IA, Cohen NA, Kreindler JL. Secondhand smoke inhibits both Cl- and K + conductances in normal human bronchial epithelial cells. Respir Res 2009, 10:120. 10.1186/1465-9921-10-120, 2792224, 19943936.
7. Clunes LA, Bridges A, Alexis N, Tarran R. In vivo versus in vitro airway surface liquid nicotine levels following cigarette smoke exposure. J Anal Toxicol 2008, 32:201-207. 10.1093/jat/32.3.201, 2994604, 18397571.
8. Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, Rowe SM. Acquired CFTR dysfunction in the lower airways in COPD. Chest 2013, 144:498-506. 10.1378/chest.13-0274, 23538783.
9. Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, Byan-Parker S, Grizzle W, Sorscher EJ, Dransfield MT, Rowe SM. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 2012, 7:e39809. 10.1371/journal.pone.0039809, 3387224, 22768130.
10. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, Worthington EN, Gentzsch M, Kreda SM, Cholon D, Bennett WD, Riordan JR, Boucher RC, Tarran R. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 2012, 26:533-545. 10.1096/fj.11-192377, 3290447, 21990373.
11. Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, Tidwell S, Tang LP, Liu B, Fortenberry JA, Jones CW, Boydston JA, Clancy JP, Bowen LE, Accurso FJ, Blalock JE, Dransfield MT, Rowe SM. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med 2013, 188:1321-1330. 10.1164/rccm.201304-0733OC, 24040746.
12. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006, 174:787-794. 10.1164/rccm.200509-1377OC, 2648063, 16840743.
13. Cho HJ, Joo NS, Wine JJ. Defective fluid secretion from submucosal glands of nasal turbinates from CFTR-/- and CFTR (DeltaF508/DeltaF508) pigs. PLoS One 2011, 6:e24424. 10.1371/journal.pone.0024424, 3164206, 21935358.
14. Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E, Conrad D, Shamsuddin AK, Durie P, Gonska T. Beta-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012, 186:732-739. 10.1164/rccm.201205-0922OC, 22859523.
15. Zhu J, Qiu Y, Valobra M, Qiu S, Majumdar S, Matin D, De Rose V, Jeffery PK. Plasma cells and IL-4 in chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:1125-1133. 10.1164/rccm.200602-161OC, 17322111.
16. Maestrelli P, Saetta M, Mapp CE, Fabbri LM. Remodeling in response to infection and injury: airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:S76-S80. 10.1164/ajrccm.164.supplement_2.2106067, 11734472.
17. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, Kazerooni EA, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Freeman C, Landreneau RJ, Wise R, Martinez FJ. Clinical significance of radiologic characterizations in COPD. COPD 2009, 6:459-467. 10.3109/15412550903341513, 19938970.
18. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest 2003, 124:2182-2191. 10.1378/chest.124.6.2182, 14665499.
19. Celli BR, Cote CG, Marin JM, Casanova C, De Montes Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012. 10.1056/NEJMoa021322, 14999112.
20. Hammond KB, Turcios NL, Gibson LE. Clinical evaluation of the macroduct sweat collection system and conductivity analyzer in the diagnosis of cystic fibrosis. J Pediatr 1994, 124:255-260. 10.1016/S0022-3476(94)70314-0, 8301433.
21. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672. 10.1056/NEJMoa1105185, 3230303, 22047557.
22. Koblizek V, Tomsova M, Cermakova E, Papousek P, Pracharova S, Mandalia RA, Ceral J, Novosad J, Fila L, Sedlak V, Ruta J, Bartos V, Salajka F, Hrnciarik M. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype. Rhinology 2011, 49:397-406.
23. Bodas M, Min T, Mazur S, Vij N. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 2011, 186:602-613. 10.4049/jimmunol.1002850, 3119853, 21135173.
24. Moran AR, Norimatsu Y, Dawson DC, Macdonald KD. Aqueous cigarette smoke extract induces a voltage-dependent inhibition of CFTR expressed in Xenopus oocytes. Am J Physiol Lung Cell Mol Physiol 2014, 306:L284-L291. 10.1152/ajplung.00163.2013, 24318115.
25. Rennolds J, Butler S, Maloney K, Boyaka PN, Davis IC, Knoell DL, Parinandi NL, Cormet-Boyaka E. Cadmium regulates the expression of the CFTR chloride channel in human airway epithelial cells. Toxicol Sci 2010, 116:349-358. 10.1093/toxsci/kfq101, 2886859, 20363832.
26. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 1998, 95:4882-4887. 10.1073/pnas.95.9.4882, 20182, 9560197.
27. Kitaguchi Y, Taraseviciene-Stewart L, Hanaoka M, Natarajan R, Kraskauskas D, Voelkel NF. Acrolein induces endoplasmic reticulum stress and causes airspace enlargement. PLoS One 2012, 7:e38038. 10.1371/journal.pone.0038038, 3364999, 22675432.
28. Hassan F, Nuovo GJ, Crawford M, Boyaka PN, Kirkby S, Nana-Sinkam SP, Cormet-Boyaka E. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One 2012, 7(11):e50837. 10.1371/journal.pone.0050837, 3511328, 23226399.
29. Bomberger JM, Coutermarsh BA, Barnaby RL, Stanton BA. Arsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cells. J Biol Chem 2012, 287:17130-17139. 10.1074/jbc.M111.338855, 3366821, 22467879.
30. Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, Tabary O, Hong SS, Boulanger P, Paulais M, Malleret L, Belaaouaj A, Edelman A, Huerre M, Chignard M, Sallenave JM. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2012, 187:170-179.
31. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183:1187-1192. 10.1164/rccm.201008-1220OC, 3114051, 21216880.
32. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agusti A. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072. 10.1164/rccm.201110-1792OC, 22427534.
33. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010, 11:63. 10.1186/1465-9921-11-63, 2891677, 20500811.
34. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580. 10.1136/thx.2003.019588, 1747070, 15223864.
35. Cote GA, Yadav D, Slivka A, Hawes RH, Anderson MA, Burton FR, Brand RE, Banks PA, Lewis MD, Disario JA, Gardner TB, Gelrud A, Amann ST, Baillie J, Money ME, O'Connell M, Whitcomb DC, Sherman S. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2011, 9:266-273. 10.1016/j.cgh.2010.10.015, 3043170, 21029787.
36. Chia SE, Lim ST, Tay SK. Factors associated with male infertility: a case-control study of 218 infertile and 240 fertile men. BJOG 2000, 107:55-61. 10.1111/j.1471-0528.2000.tb11579.x, 10645862.
37. Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008, 134:1244-1249. 10.1378/chest.07-3054, 18641115.
38. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013, 143:14-18. 10.1378/chest.12-1430, 23276841.